Kelley Weinfurtner, MD
Assistant Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
421 Curie Blvd, 910 BRB II/III
Philadelphia, PA 19104
Philadelphia, PA 19104
Education:
BA (Bachelor of Arts, Molecular and Cell Biology)
University of California Berkeley, 2007.
MD (Doctor of Medicine)
University of California San Francisco, 2015.
MSTR (Translational Research)
University of Pennsylvania, 2024.
Permanent linkBA (Bachelor of Arts, Molecular and Cell Biology)
University of California Berkeley, 2007.
MD (Doctor of Medicine)
University of California San Francisco, 2015.
MSTR (Translational Research)
University of Pennsylvania, 2024.
Description of Clinical Expertise
I am a transplant hepatologist who cares for patients with a wide range of liver problems. In particular, I have significant expertise in caring for patients with advanced liver disease and patients with liver tumors.Description of Research Expertise
My research is centered around developing precision medicine strategies for patients with primary liver cancers. In particular, I have expertise in developing patient-derived models of primary liver cancer for use in translational therapeutics.Selected Publications
Yohan Kim, George McClung, Cecilia Wright, David Tischfield, Emma E Furth, Eleana Kaffe, Kelley Weinfurtner, Terence P Gade: Hepatocyte Humanization in an SRG Rat Model After Partial Hepatectomy. AASLD Liver Meeting November 2025.Maarouf A. Hoteit, Peter L. Abt, Salvatore F. Priore, Rashmi Tondon, Samir Abu-Gazala, Parul Agarwal, Kelley Weinfurtner, Moira B. Hilscher, Kirk J. Wangensteeen: Molecular patterns associated with recurrence and survival in intrahepatic cholangiocarcinoma (iCCA) / hepatocholangiocarcinoma (HCC-CCA) after liver transplantation. AASLD Liver Meeting November 2025.
Hoteit M, Weinfurtner K: Recurrent hepatocellular carcinoma after liver transplantation: Small steps, while awaiting a breakthrough. Liver Transplantation April 2025 Notes: Online ahead of print. doi: 10.1097/LVT.0000000000000571.
Kelley Weinfurtner, David Tischfield, George McClung, Jennifer Crainic, John Gordan, Jing Jiao, Emma E. Furth, Wuyan Li, Erena Tuzneen Supan, Gregory J. Nadolski, Stephen J. Hunt, David E. Kaplan, Terence P.F. Gade: Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts. JHep Reports 7(3): 101264, March 2025 Notes: https://doi.org/10.1016/j.jhepr.2024.101264.
Willis E, Verrelle J, Secreto A, Cole S, McClung G, Weinfurtner K, Gade TP, Radaelli E: Diagnostic Challenge in Veterinary Pathology: Otitis Media in a Humanized NOG-EXL Mouse. Vet Pathol 62(2): 113-116, March 2025.
Huang L, Dang QA, Wright, C, Gade TPF, Weinfurtner, K: Comparison of treatment response to chemoembolization and radioembolization in patients with intermediate stage hepatocellular carcinoma. Society of Interventional Oncology Annual Meeting February 2025 Notes: POSTER.
Habibollahi P, Gurevich A, Hui JZ, Weinfurtner K, McClung G, Adler J, Soulen MC, Kaplan DE, Nadolski GJ, Hunt SJ, Tsourkas A, and Gade TP: Integrated imaging probe and bispecific antibody development enables in vivo targeting of glypican-3-expressiong hepatocellular carcinoma. Mol Cancer Ther 23(12): 1815-1826, December 2024.
Wong JC, Weinfurtner KM, Westover T, Kim J, Lebish EJ, Alzamora Mdel, Walsh M, Abdelhamed S, Ma J, Klco JM, Shannon K. : 5G2 mutant mice model loss of commonly deleted segment of chromosome 7q22 in myeloid malignancies. Leukemia 38(5): 1182-1186, May 2024.
Nicole Ferrante, Rebecca Hubbard, Kelley Weinfurtner, Anya I Mezina, Craig Newcomb, Emma E Furth, Debika Bhattacharya, Basile Njel, Tamar H Taddei, Amit G Singal, Maarouf Hoteit, Lesley S Park, David E Kaplan, Vincent Lo Re: Development and validation of case-finding algorithms to identify cholangiocarcinoma and its subtypes in Veterans Health Administration data. Digestive Disease Week May 2024 Notes: POSTER.
Quynh-Anh L Dang, Kelley Weinfurtner, Gregory J Nadolski, Stephen J Hunt, Terence P Gade: Prolonged Treatment Response With Radioembolization Compared to Chemoembolization in Early Stage Hepatocellular Carcinoma Patients Ineligible for Curative Therapy. SIR Annual Meeting March 2024 Notes: POSTER.